CN1504185A - Medicine composition - Google Patents
Medicine composition Download PDFInfo
- Publication number
- CN1504185A CN1504185A CNA200310118681A CN200310118681A CN1504185A CN 1504185 A CN1504185 A CN 1504185A CN A200310118681 A CNA200310118681 A CN A200310118681A CN 200310118681 A CN200310118681 A CN 200310118681A CN 1504185 A CN1504185 A CN 1504185A
- Authority
- CN
- China
- Prior art keywords
- composition
- pharmaceutical composition
- record
- taking
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 229940079593 drug Drugs 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 24
- 210000002784 stomach Anatomy 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 19
- 238000007908 dry granulation Methods 0.000 claims description 11
- 239000004083 gastrointestinal agent Substances 0.000 claims description 11
- 229940127227 gastrointestinal drug Drugs 0.000 claims description 11
- 229960004291 sucralfate Drugs 0.000 claims description 5
- 241000531495 Corydalis edulis Species 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 claims description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 claims description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 2
- IVVHAAOJLULJLK-YDXSIYMFSA-E Aceglutamide aluminum Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3].CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O.CC(=O)N[C@H](C([O-])=O)CCC(N)=O IVVHAAOJLULJLK-YDXSIYMFSA-E 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 229920001386 Gefarnate Polymers 0.000 claims description 2
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 claims description 2
- FSRLGULMGJGKGI-BTJKTKAUSA-N Trimebutine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 FSRLGULMGJGKGI-BTJKTKAUSA-N 0.000 claims description 2
- YSIITVVESCNIPR-UHFFFAOYSA-N Troxipide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC2CNCCC2)=C1 YSIITVVESCNIPR-UHFFFAOYSA-N 0.000 claims description 2
- 229960002627 aceglutamide aluminum Drugs 0.000 claims description 2
- 229950008605 aclatonium Drugs 0.000 claims description 2
- SRZGFCNCQUMTCP-UHFFFAOYSA-N aclatonium Chemical compound CC(=O)OC(C)C(=O)OCC[N+](C)(C)C SRZGFCNCQUMTCP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000507 anthelmentic effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 229940029980 drug used in diabetes Drugs 0.000 claims description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001596 famotidine Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 229960003779 gefarnate Drugs 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- 229960004872 nizatidine Drugs 0.000 claims description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 2
- 229960000381 omeprazole Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 2
- SUWYPNNPLSRNPS-UNTSEYQFSA-N plaunotol Chemical compound CC(C)=CCC\C(C)=C\CC\C(CO)=C\CC\C(C)=C\CO SUWYPNNPLSRNPS-UNTSEYQFSA-N 0.000 claims description 2
- 229950009291 plaunotol Drugs 0.000 claims description 2
- SUWYPNNPLSRNPS-UHFFFAOYSA-N plaunotol Natural products CC(C)=CCCC(C)=CCCC(CO)=CCCC(C)=CCO SUWYPNNPLSRNPS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003857 proglumide Drugs 0.000 claims description 2
- 229960003320 roxatidine Drugs 0.000 claims description 2
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 claims description 2
- 229950004782 sofalcone Drugs 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 229950006156 teprenone Drugs 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 229960005345 trimebutine Drugs 0.000 claims description 2
- 229960001341 troxipide Drugs 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 1
- 229960000620 ranitidine Drugs 0.000 claims 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 15
- 235000019640 taste Nutrition 0.000 abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 235000000346 sugar Nutrition 0.000 abstract description 4
- 235000003599 food sweetener Nutrition 0.000 abstract description 3
- 239000003765 sweetening agent Substances 0.000 abstract description 3
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 2
- 230000000873 masking effect Effects 0.000 abstract 2
- 150000008163 sugars Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 19
- 238000005469 granulation Methods 0.000 description 14
- 230000003179 granulation Effects 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 230000000996 additive effect Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 235000019658 bitter taste Nutrition 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 229940041616 menthol Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- 238000000748 compression moulding Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- JTZPPHUZZDKEOC-RBQAPOGLSA-A chembl2367706 Chemical compound O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 JTZPPHUZZDKEOC-RBQAPOGLSA-A 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- -1 silicic acid magnesium aluminate Chemical class 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 235000019606 astringent taste Nutrition 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 238000009775 high-speed stirring Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- FIUBOPPLFYFRMW-UHFFFAOYSA-E aluminum;trimagnesium;carbonate;heptahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Al+3].[O-]C([O-])=O FIUBOPPLFYFRMW-UHFFFAOYSA-E 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 229960001545 hydrotalcite Drugs 0.000 description 2
- 229910001701 hydrotalcite Inorganic materials 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CQONVBIGUJWUFE-UHFFFAOYSA-N Butoctamide hydrogen succinate Chemical compound CCCCC(CC)CNC(=O)CC(C)OC(=O)CCC(O)=O CQONVBIGUJWUFE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- NQNOPCNLUXAQJW-UHFFFAOYSA-N Cl.N1CCNCC1.[Cl] Chemical compound Cl.N1CCNCC1.[Cl] NQNOPCNLUXAQJW-UHFFFAOYSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- IWQQNDAAVPMDJR-UOOQWULYSA-L Ferrotrenine Chemical compound O.O.[Fe++].C\C=N\C(C(C)O)C([O-])=O.C\C=N\C(C(C)O)C([O-])=O IWQQNDAAVPMDJR-UOOQWULYSA-L 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000246500 Gentianella aspera Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710098556 Lipase A Proteins 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- UZIQYAYUUNMDMU-UHFFFAOYSA-N N.[Br+] Chemical compound N.[Br+] UZIQYAYUUNMDMU-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 101710095911 Protein yippee-like 1 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- LMAQHEGFQZGATE-UHFFFAOYSA-N Tinoridine hydrochloride Chemical compound Cl.C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 LMAQHEGFQZGATE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 235000009932 Zanthoxylum simulans Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 229940024223 alseroxylon Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- PCRDIRUKXOTDNN-UHFFFAOYSA-K aluminum;sodium;carbonate;hydroxide Chemical compound [OH-].[Na+].[Al+3].[O-]C([O-])=O PCRDIRUKXOTDNN-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950006519 butoctamide Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 229950008011 diprofene Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- BSHWLCACYCVCJE-UHFFFAOYSA-N eprazinone Chemical compound C=1C=CC=CC=1C(OCC)CN(CC1)CCN1CC(C)C(=O)C1=CC=CC=C1 BSHWLCACYCVCJE-UHFFFAOYSA-N 0.000 description 1
- 229960002561 eprazinone Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229950002211 ferrotrenine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- YUFWAVFNITUSHI-UHFFFAOYSA-N guanethidine monosulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.NC(=N)NCCN1CCCCCCC1 YUFWAVFNITUSHI-UHFFFAOYSA-N 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- WFLSCFISQHLEED-UHFFFAOYSA-N isoaminile Chemical compound CN(C)C(C)CC(C(C)C)(C#N)C1=CC=CC=C1 WFLSCFISQHLEED-UHFFFAOYSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229950007634 kitasamycin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- WEXRVFDKZKSKQS-UHFFFAOYSA-N s-[2-(dipropylamino)ethyl] 2,2-diphenylethanethioate Chemical compound C=1C=CC=CC=1C(C(=O)SCCN(CCC)CCC)C1=CC=CC=C1 WEXRVFDKZKSKQS-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Inorganic materials [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 1
- 229940075581 sodium bromide Drugs 0.000 description 1
- IDBYLPRJLWSMAI-UHFFFAOYSA-M sodium;1,2,3,3a,4,5,6,7,8,8a-decahydroazulene-1-sulfonate Chemical compound [Na+].C1CCCCC2C(S(=O)(=O)[O-])CCC21 IDBYLPRJLWSMAI-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- PRZPUYBFEJPNPF-UHFFFAOYSA-J tetrasodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-] PRZPUYBFEJPNPF-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229950001089 todralazine Drugs 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided is a medicinal composition effective for solving the problem of the increase in tablet size to cause difficulty in taking caused by the use of a large amount of additives other than an active component for masking the disagreeable taste of the active component, and the problem of the use of mainly a sweetener for the masking of the disagreeable taste of the active component to cause inadequency from the view point of preference of a person of stomach discomfort to hate a medicine necessitating a high administration dose and having strong sweetness and that of the restriction for a person of diabetes, or the like, restricted to take sugars.This medicinal composition having improved administration feeling contains the active component giving discomfortable feeling when taking in combination with a stomachic herb drug. The pharmaceutical composition can reduce the use of additives such as sweetener and mask the taste of a component giving discomfortable feeling in taking.
Description
Technical field
In the oral cavity, produce bitterness when the present invention relates to take, when tart flavour, the active ingredient preparation of senses of discomfort such as astringent taste, suppress pharmaceutical composition of its sense of discomfort effect excellence and preparation method thereof.Further, the present invention relates to produce the covering method of the active ingredient of sense of discomfort such as above-mentioned bitterness, and above-mentioned sense of discomfort is suppressed the use of the crude drug of effect excellence as screening agent.
Background technology
In the physiologically active ingredient as the medicine use, in the oral cavity, produce bitterness when taking, tart flavour, the composition of senses of discomfort such as astringent taste is a lot.In order to relax, the sense of discomfort when suppressing this taking has been carried out various trials.
Past in order to alleviate the bitterness of ascorbic acid calcium salt, has proposed the mixing aspartame, water-soluble saccharides (reduction maltose) and free physiologically active ingredient as required, the invention of compression molding preparationization.In this communique, the compression molding preparation of the bitterness of long-time inhibition ascorbic acid calcium salt is disclosed, its preparation method, and covering method.In addition, the invention of putting down in writing in this communique, the special sense of discomfort flavor that suppresses glucide also is purpose (for example, Japanese documentation 1).
But, the invention of putting down in writing in this communique, the use amount of additive reduction maltose is many, and tablet maximizes and is difficult to take, and exists device to maximize problems such as particularization in the manufacturing.In addition, this invention relates to the content of compression molding preparation, and dosage form for example is defined as fancy food or tablets such as drop, confection, contains tablet, and oral cavities such as SHEXIAPIAN tablet can not be expected powder, the effect of dosage forms such as granule.
The formability preparation (for example, Japanese documentation 2) of the water-soluble saccharides of the slaine that contains based on the physiologically active ingredient with bitterness, glucide, reduction maltose is disclosed in addition.
But, with above-mentioned compression molding preparation similarly, the use amount of water-soluble saccharides such as additive reduction maltose is many, produces tablet and maximizes and take difficulty, device maximizes in the preparation, problems such as particularization.In addition, can not expect powder, the effect of dosage forms such as granule.
In addition, disclose in the mixture of composition with uncomfortable flavor and correctives and applied the body of powder that shear strength obtains, perhaps added the paraffin composition in the body of powder, further will apply the granulation compositions of having sheltered the sense of discomfort flavor that the body of powder of shear strength is granulated and formed.And, can enumerate saccharide, synthetic sweetener, aminoacid, acidic flavoring agent etc. as correctives.The purpose of the invention of this communique record provides and is suppressed at the discomfort flavor of feeling in the mouth, has the successive granulation compositions of good flavoring and this effect.In addition, be purpose (for example, Japanese documentation 3) so that cheap equipment, simple preparation method to be provided
But the manufacture method of granulation compositions is made of simple operation, but the pelletize compositions in order to obtain sheltering, it is indispensable cutting off processing.Therefore, cut off processing increase operation, on the manufacturing cost this point, have problems owing to operate this.And, owing to be to have the composition of uncomfortable flavor, be difficult to from the problem of granulation thing stripping effective ingredient after having so-called administration by the form that the paraffin composition surrounds.
Like this, above-mentioned prior art is common to be to use principal agent composition additive in addition in a large number, mainly uses sweeting agent to suppress sense of discomfort.Can enumerate aspartame as sweeting agent, glucide (gluside), reduction maltose etc.But, showing that for stomach people's dose of sense of discomfort symptom is many, it is suitable that the preparation that sweet taste is strong can not be said so from the viewpoint of hobby property.In addition, also there is the problem of difficulty in fact in the people's administration for this class restriction sugar picked-up of diabetes.
[Japanese documentation 1]
No. 3110299 communique of Japan Patent (the 1st～4 hurdle)
[Japanese documentation 2]
The open 2000-103746 communique (the 1st～3 hurdle) of Japan Patent
[Japanese documentation 3]
The open 2000-191517 communique (the 1st～3 hurdle) of Japan Patent
As mentioned above, invention disclosed in the prior art document is because a large amount of principal agent composition additive in addition that uses under the situation as tablet formulation, exists so-called tablet to maximize and takes the problem of difficulty.In addition, mainly, use sweeting agent to suppress the discomfort flavor of effective ingredient, can enumerate aspartame as sweeting agent, glucide, reduction maltose etc.But, showing that for stomach people's dose of sense of discomfort class symptom is too much, it is suitable that the preparation that sweet taste is strong can not be said so from the viewpoint of hobby property.In addition, there is the administration problem of difficulty in fact in the people who limits sugar picked-up like that for diabetes.
Therefore, aspect additive use amount reductions such as sweeting agent, expectation can suppress to take the pharmaceutical composition of taste of the composition of sense difference, with and preparation method thereof exploitation.In addition, as its preparation method, expectation is made of simple operation, and process number is few, preparation method cheaply.
Summary of the invention
Present inventors, in order to solve above-mentioned problem, the result of further investigation, the physiologically active ingredient that produces sense of discomfort when making us finding uncannily to take mixes with the crude drug that is good for the stomach, and when taking said composition, has relaxed this sense of discomfort down to having finished the present invention.Owing in the original effect that is good for the stomach of the crude drug composition that keeps being good for the stomach, work as correctives, can successfully reduce the use amount of the additives such as sweeting agent that the past uses as correctives for physiologically active ingredient.Therefore, during preparation of drug combination of the present invention, the wet granulation method that discovery need not be common is suitable for the dry granulation method.That is, in the pharmaceutical composition of the present invention by the dry granulation manufactured, be surprised to find that the flavoring effect of comparing blended crude drug with simple mixture increases, and, the sense of taking that has improved pharmaceutical composition.
Take the medicine that digestive tract side effects occurs, or in mouth, produce the physiologically active ingredient of sense of discomfort when taking,, can reduce or eliminate above-mentioned side effect, in addition, can shelter uncomfortable taste by making pharmaceutical composition of the present invention.
In addition,, in mouth, produce the physiologically active ingredient of sense of discomfort and the crude drug that is good for the stomach mixing when taking, can shelter uncomfortable taste by the gastrointestinal drug composition beyond the crude drug that will be good for the stomach.And, can obtain gastrointestinal drug and the crude drug effect that multiplies each other of drug effect separately that is good for the stomach.
The specific embodiment
The present invention when producing the physiologically active ingredient preparation of sense of discomfort in the time will taking, can extensively utilize.Can be listed below as these compositions.During preparation, can mix following compositions more than a kind and 2 kinds.And, they and other active ingredient can be made up and preparationization.
(1) gastrointestinal drug composition is taken the composition example of sense difference
1) can enumerate following ingredients as drug for peptic ulcer.
Sucralfate, aceglutamide aluminum, gefarnate, sulpiride, lattice dragon bromine ammonium, proglumide, sofalcone, teprenone, Amicos (Banyu), troxipide, plaunotol, (the thunder mud is for fourth for histamine H2 receptor antagonist, cimetidine, famotidine, nizatidine, roxatidine), proton pump inhibitor (omeprazole)
2) digestive organs medication
Metoclopramide, aclatonium napadisilate, Trimebutine Maleate etc.
3) as antacid
Aluminium Hydroxide, silicic acid magnesium aluminate, magnesium silicate, synthetic aluminium silicate, synthetic hydrotalcite, magnesium oxide, aluminum magnesium hydroxide, aluminium hydroxide-sodium bicarbonate coprecipitated product, aluminium hydroxide-magnesium carbonate combination drying gel, aluminium hydroxide-magnesium carbonate coprecipitated product, magnesium hydroxide, sodium bicarbonate, magnesium carbonate, winnofil, silicic acid magnesium aluminate, calcium phosphate dibasic anhydrous, calcium hydrogen phosphate etc.
In mouth, produce the composition example of sense of discomfort when (2) biological active substances with digestive system side effect is taken
1) hypnosis tranquilizer:
Barbital, sodium bromide, Butoctamide Semisuccinate, Zopiclone etc.
2) antipyretic analgesic:
Acetaminophen, mefenamic acid, aspirin, ethenzamide, isopropylantipyrine, diclofenac sodium, ibuprofen, ketoprofen, indomethacin, Dimaten (Promeco) etc.
3) relieving cough and eliminating sputum medicine:
Dihydrocodeine phosphate, dextromethmorphan hydrobromide, Perocan (Toyo Jozo)., hydrochloric acid eprazinone, this fourth of hydrochloric acid chlorine piperazine, narcotine, guaiacol, potassium sulfonate, ephedrine hydrochloride, dl-hydrochloride methyl ephedrine etc.
4) antihistaminic:
Chlorphenamine maleate, phentolamine hydrochloride, clemastine fumarate etc.
5) cardiac tonic:
Aminophylline, diprofene, digitophyllin etc.
6) the dizzy medicine in town:
Dimenhydrinate, difenidol hydrochloride, dl-isoprenaline etc.
7) diabetes medication:
The hydrochloric acid metformin, andere etc.
8) hypotensor:
Todralazine Hydrochloride, alseroxylon, guanethidine monosulphate, clonidine hydrochloride etc.
9) inorganic formulation:
Potassium gluconate, potassium chloride, iron sulfate, ferrotrenine, tetrasodium biscitrate ferrate etc.
10) hormone:
Dexamethasone, betamethasone etc.
11) antibiotic:
Cefradine, cefaclor, erythromycin, clarithromycin, kitasamycin, midecamycin, tetracycline, oxytetracycline, chloromycetin, lincomycin hydrochloride, a kanamycin sulfate, paromomycin sulfate, Lyphocin (Fujisawa) etc.
12) anthelmintic, disease-resistant protozoon agent:
The citric acid diethylcarbamazine, thiabendazole, quinin hydrochloride, quinine sulfate, tinidazole etc.
For above-mentioned physiologically active ingredient, when taking, what is called produces sense of discomfort, be meant bitterness, astringent taste, acid, astringent taste, ferrum flavor, powder flavor, coarse sense of taste etc.
In addition,, for example can enumerate the demonstration inappetence as above-mentioned digestive system side effect, the stomach discomfort sense, stomachache, the abdominal part sensation of fullness, constipation is felt sick, vomiting, symptoms such as diarrhoea.
As the crude drug that is good for the stomach that uses in the invention pharmaceutical composition, can enumerate following crude drug group.This crude drug powder can select combination more than 1 or 2 in crude drug group as follows.
The crude drug group: Cortex cinnamomi japonici (Ramulus Cinnamomi), Flos Caryophylli, Rhizoma Zingiberis Recens, Fructus Foeniculi, Radix Gentianae, Radix Curcumae, Pericarpium Zanthoxyli, Pericarpium Citri Reticulatae, Rhizoma Alpiniae Officinarum, Cortex Phellodendri, Herba corydalis edulis, Rhizoma Coptidis is worked as medicine, Cortex Magnoliae Officinalis, Radix Paeoniae, Fructus Amomi, Radix Glycyrrhizae, Radix Scutellariae, Ramulus Et Folium Picrasmae, Rhizoma Atractylodis, Radix Ginseng, Fructus Evodiae
As follows from effective combination of these crude drug group selections.Dosage, the suitable scope of the present invention of expression.In addition, the combination of the crude drug that uses in the pharmaceutical composition of the present invention is without any qualification.
Dosage
Cortex cinnamomi japonici (Ramulus Cinnamomi) 50～333mg
Flos Caryophylli 10～50mg
Rhizoma Zingiberis Recens 10～100mg
Fructus Foeniculi 10～100mg
Radix Gentianae 10～50mg
Radix Curcumae 10～100mg
Pericarpium Zanthoxyli 2～30mg
The kind and the dosage of other crude drug of suitable pharmaceutical composition of the present invention are as follows.For these combinations, replace mentioned component to mix, also can in mentioned component, add.
Dosage
Pericarpium Citri Reticulatae 10～100mg
Rhizoma Alpiniae Officinarum 10～100mg
Cortex Phellodendri 10～50mg
Herba corydalis edulis 10～150mg
Rhizoma Coptidis 10～50mg
As medicine 10～50mg
Cortex Magnoliae Officinalis 10～100mg
Radix Paeoniae 10～100mg
Fructus Amomi 10～150mg
Radix Glycyrrhizae 10～150mg
Radix Scutellariae 10～50mg
Ramulus Et Folium Picrasmae 10～50mg
Rhizoma Atractylodis 10～50mg
Radix Ginseng 10～150mg
Fructus Evodiae 10～100mg
As the dosage form of the crude drug that is good for the stomach that uses in the pharmaceutical composition of the present invention, be preferably the powder or the dry extract of pulverizing.In addition, comminuted powder more preferably.The particle diameter of crude drug powder is preferably below the 500 μ m, more preferably below the 300 μ m, most preferably is below the 150 μ m.The composition that the combined amount of crude drug powder is taken the sense difference with respect to 1 weight portion is 0.2 weight portion～2 weight portions, more preferably 0.2 weight portion～1.0 weight portions.
When the pulverizing of above-mentioned crude drug, can use common method, rotary type for example, fluid-type, grinding modes such as impact type.In addition, also can with crude drug with liquid nitrogen freezing after lyophilizing pulverize.
Pharmaceutical composition of the present invention can carry out following preparationization.
The physiologically active ingredient that produces sense of discomfort during with taking more than a kind or 2 kinds be good for the stomach crude drug, and other physiologically active ingredient, additive etc. as required mixes with V-Mixer, it is used the roller type press compression molding, manufacture thin slice, it is waited with the roller pulverizer vibration carry out granulate then.
During above-mentioned mixing, also can use beyond the V-Mixer Wtypeofblender, bump container mixer, High Speed Stirring Machine, omnipotent stirring mixer etc.
During wet granulation, can use rotation granulator, mixer granulator, fluidized bed granulator, spray granulation machine, centrifugal rotation granulator, wet granulation machines such as rotational flow granulator.On the other hand, during the dry granulation method, can use the dry granulation machines such as compacting granulator of the granulous binding agent of usefulness powder etc.Also not too damage the effect of sheltering uncomfortable taste even granulate in any way, but the dry granulation method owing to do not comprise heating process, has kept the local flavor of crude drug, can obtain having the pharmaceutical composition of better taking sense.So-called dry granulation method is with having highly compressed roller compaction body of powder, shaping, the method for the thing that further its granulate obtained granulating.
As above-mentioned wet granulation method, use mixer granulator or fluidized bed granulator, the solution that has dissolved water equal solvent or binding agent is added in the body of powder granulate.In addition, can use body of powder dissolving or be distributed in the water equal solvent, with its spray-drying process method of granulating with spray drying etc.Because by these method for making drying and granulating goods, goods will heat for a long time.Because by such heating, reduced the flavored action of the desired crude drug of the present invention, under the situation about making by these method for makings, with these methods granulations, it is effective then crude drug being mixed under non-heating condition with the composition beyond the crude drug.
If the powder body made from the method for making that do not heat, can be with its compression molding (tabletting).The form of tablet can single-layer sheet, in addition, also can be two layers, three-layer tablet.
Pharmaceutical composition of the present invention also can be the dosage form of the aqueous dispersions preparation of the physiologically active ingredient of uncomfortable taste and crude drug powder.
Pharmaceutical composition of the present invention except that discomfort is taken sense composition and crude drug, also can contain other biological active substances.For example, if gastrointestinal drug can further mix antacid, digestive pharmaceutical, medicines for relieving intestinal disorders, mucosa renovation agent, diarrhea.
And, during preparation, can mix additive commonly used.The kind and the quantity of additive are not particularly limited, but the quantitative change of additive is many, and it is important that the single administration amount is exceeded.In addition, use saccharide in large quantities, it is necessary that preparation did not become sweet.As additive, can use for example following material.
Crystalline cellulose, lactose, white sugar, corn starch, potato starch, polyvinyl alcohol, calcium stearate, magnesium stearate, sucrose fatty acid ester, stearic acid, Carmellose, Carmellose calcium, carmellose sodium, big carmellose sodium (croscarmellosesodium), the low hydroxypropyl cellulose that replaces, carboxymethyl starch sodium, aqueous silicon dioxide, light silicon anhydride, titanium oxide, Talcum, gastric solubility acrylic resin, arabic gum, carboxyl ethylene polymer, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose etc.
The preparation of drug combination method according to the present invention can prepare with cheap simple equipments ground.In addition, according to the present invention,, can eliminate the problem that the such tablet of prior art maximizes owing to can reduce the use amount of additives such as sweeting agent.And, also can be dosage forms such as powder and granule.
[embodiment]
The present invention further describes by the following example, but the present invention is not limited to these
Embodiment.
[embodiment 1～9]
By the prescription shown in 1 of tabulating down, each dry powdered composition of ormal weight is collected in the polyester bag, carry out simple mixing.Merely mixing ratio writes out a prescription 1～4 under same condition, and as a comparative example 1～4.
Take a dose respectively for 10 experimenters, obtain the evaluation in 10 stages by the experimenter these drying composites.With its mean deviation of counting as the functional evaluation result.And, based on this standard determination below equalization point.And the composition that uncomfortable taste is arranged when taking is a sucralfate.
Criterion: *: poor (the functional evaluation result: 1 above less than 3) △: common (functional evaluation result: 3 above less thaies 6) zero: good (functional evaluation result: 6 above less thaies 8) ◎: very good (functional evaluation result: more than 8 below 10) of sense taken
[table 1]
| (mg) embodiment (mg) relatively writes out a prescription | ||
| Prescription No. | ①??????②?????③?????④ | 1????2????3????4????5????6????7????8????9 |
| Ulcerlmin azulene sodium sulfonate Pidolidone sodium acid carbonate synthesizes Hydrotalcite AMS SS lipase A P6 cassia bark fructus amomi cloves ginger fennel rough gentian dried orange peel Chinese pepper root tuber of aromatic turmeric | 500?????500????500????500 2???????2??????2??????2 134?????134????134????134 150?????300????150????300 160?????160????160????160 20??????20 20??????20 | 500??500??500??500??500??500??500??500??500 2????2????2????2????2????2????2????2????2 134??134??134??134??134??134??134??134??134 150??150??150??300??150??150??300??300??150 160??160??160??160??160??160??160??160??160 ?????????????????????????20???20????20 ?????????????????????????20???20????20 120??150??100??60???100??100??100??100??100 80???50???30 ?????30???10????????10???10???10???20???40 25???25???20???30???30???30???30???30???40 25???50???15???12????????20???20???10???20 ???????????????12????????10???10???10???10 50????????30???12???30????????30???15 ??????????15???18???10?????????????15???4 ???????????????30???????????????????????20 |
| Crude drug adds up to | 300??305??220??174??180??170??200??200??234 | |
| Crude drug weight ratio with respect to sucralfate | 0.6??0.61?0.44?0.35?0.36?0.34?0.4??0.4??0.47 | |
| Mannitol L-menthol | 50???80???50???50???50???50???50???50???50 10???5????3????6????2????2????2????2????2 | |
| Add up to (1 dose) to estimate 10 stages of point | 946?????1096????986????1136 3???????2.5?????2.5????2.5 ×??????????????×?????????????×?????????????× | 1307?1337?1219?1326?1178?1208?1388?1388?1232 6.6??6????6.4??6.4??5.2??6.5??7.5??7.3??8 ○???○???○???○???○???○???○???○???◎ |
From the function test result, confirm to have improved the sense of taking of sucralfate by the mixing crude drug that is good for the stomach.
[test example]
With the prescription shown in the following table 2, will take for 10 special experimenters by the preparation of following various method of granulating manufacturings, obtain taking the evaluation of sense by the experimenter.
[table 2]
(1) extruding is granulated
Get a part of 3g of binding agent, adding water, to make total weight be 25g, as binding agent liquid.The mentioned component of L-menthol is removed in weighing, drops into High Speed Stirring Machine NMG-1L (strain) nara machinery and makes made) in, mixed 1 minute.Drop into above-mentioned binder solution then, in High Speed Stirring Machine, mixed 1 minute.For this mixture, push granulation by the granulator Dome Gran DGL-1 (Fuji Paudal (strain) system) that 0.6mm sieve has been installed.And, the granulation thing is handled with the sphering that Marmerizer O-230 (Fuji Paudal (strain) system) carries out about 30 seconds, with its at 60 ℃ with SAFTY OVEN SPH-101 (ESPEC (strain) system) drying 3 hours.According to the yield of making thing, calculate the amount of menthol, weighing is pulverized it with mortar, add the granule of manufacturing to.
(2) fluidized bed pelletize
Get the 2g binding agent, become 50g to wherein adding entry, dissolving is called binding liquid.Further, the mentioned component that menthol is removed in weighing sieves, and mixes in polymer pouches.Mixture is packed in the fluidized bed granulator New Marmeizer NQ-125 type (Fuji Paudal (strain) system); above-mentioned binder solution is granulated (to 60 ℃ in gas with top spray (top-spray) fluidized bed; 35 ℃ of product temperature), then, by fluidized bed 60 ℃ of dryings 30 minutes.With the granulation thing with the sub-granulate of 30 mesh sieves, will by 30 purpose products and (1) similarly menthol mortar milling product mix.
(3) spray drying 1
The mentioned component of menthol is removed in weighing, is adjusted into the aqueous dispersions that solid constituent is 30wt%.For this dispersion liquid spray dryer-L-8 type (the former worker's machine in great river (strain) system), in the about 120 ℃ of following spray dryinges of inlet temperature.In this granulation thing with (1), the mixing menthol ground product that (2) are same.
(4) spray drying 2
Weighing is removed menthol and the mentioned component of the crude drug that is good for the stomach, and is adjusted into the aqueous dispersions that solid formation is divided into 30wt%.For this dispersion liquid spray dryer-L-8 type (the former worker's machine in great river (strain) system), in the about 120 ℃ of following spray dryinges of inlet temperature.The menthol comminuted powder is mixed in polymer pouches with the granulation thing with crude drug powder.
(5) dry granulation
With the mentioned component weighing, sieve, put into roller type press-WP90 * 30 (TURBO KOGYO (strain) system) and compression, sheet.Then, this thin slice is vibrated granulate with roller pulverizer-GRN-T53S (Japanese グ ラ ニ ュ レ--(strain) system) with 30 purposes.
(6) simple mixing
With the mentioned component weighing, in polymer pouches, mix.
The preparation of method for making manufacturing that will be by above-mentioned (1)～(6) takes for respectively 10 special experimenters, and it takes the following standard evaluation of sense.
Standard: * tasty, △ is slightly somewhat tasty, and zero drinks well reluctantly, and ◎ drinks well
The results are shown in down tabulation 3.
[table 3]
The result
Method for making is estimated
Simple mixing zero
Spray drying 1 △
Spray drying 2 zero
Dry granulation ◎
Extruding granulation △
Fluidized bed granulation △
The preferred granulation process, particularly preferred dry granulation that uses crude drug without long-time heating.
The physiologically active ingredient that will produce sense of discomfort by will take the time mixes with the crude drug that is good for the stomach, in the original effect that is good for the stomach of the crude drug composition that keeps being good for the stomach, as its effect of correctives, successfully reduce the use amount of the additives such as sweeting agent that use under the existing purpose for physiologically active ingredient.And, owing to can pass through the dry granulation manufactured, further increase as the effect of correctives, improved and taken sense.
Medicine by use finding the digestive system side effect or the physiologically active ingredient that produces sense of discomfort when taking in mouth are made pharmaceutical composition of the present invention, can reduce or eliminate above-mentioned side effect, in addition, can shelter sense of discomfort.In addition, use gastrointestinal drug beyond the crude drug that is good for the stomach, when producing the physiologically active ingredient of sense of discomfort in the mouth when taking, can shelter uncomfortable taste by the mixing crude drug that is good for the stomach.And, can expect gastrointestinal drug and the crude drug effect that multiplies each other of drug effect separately that is good for the stomach.
And pharmaceutical composition of the present invention because the people of the such restriction sugar of diabetes picked-up takes them easily, has with the selection of Therapeutic Method extensively, and the expansion and contraction of taking medicine rises to main huge effect.
And, according to the manufacture method of pharmaceutical composition of the present invention, can make by cheap simple equipments ground.In addition, eliminated the maximization problem of so-called tablet, made the supply of various dosage forms such as powder beyond the tablet or granule become possibility.
Claims (12)
1, contain when taking the composition that produces sense of discomfort and the crude drug that is good for the stomach, improved the pharmaceutical composition of taking sense.
2, the pharmaceutical composition of claim 1 record is characterized in that reducing the use amount of correctives.
3, the pharmaceutical composition of claim 1 or 2 records, the wherein above-mentioned crude drug that is good for the stomach is powder or the dry extract of pulverizing.
4, the pharmaceutical composition of claim 3 record, the comminuted powder of the wherein above-mentioned crude drug that is good for the stomach or the particle diameter of dry extract are below the 500 μ m.
5, the pharmaceutical composition of claim 1 record, the combined amount of the wherein above-mentioned crude drug that is good for the stomach, the composition of generation sense of discomfort is 0.2 ~ 2 weight portion when taking with respect to 1 weight portion.
6, the pharmaceutical composition of claim 1 record, the composition that produces sense of discomfort during wherein above-mentioned taking is the gastrointestinal drug composition.
7, the pharmaceutical composition of claim 1 record, the wherein above-mentioned crude drug composition that is good for the stomach is from Cortex cinnamomi japonici (Ramulus Cinnamomi), Flos Caryophylli, Rhizoma Zingiberis Recens, Fructus Foeniculi, Radix Gentianae, Radix Curcumae, Pericarpium Zanthoxyli, Pericarpium Citri Reticulatae, Rhizoma Alpiniae Officinarum, Cortex Phellodendri, Herba corydalis edulis, Rhizoma Coptidis is worked as medicine, Cortex Magnoliae Officinalis, Radix Paeoniae, Fructus Amomi, Radix Glycyrrhizae, Radix Scutellariae, Ramulus Et Folium Picrasmae, Rhizoma Atractylodis, selection is made up more than 1 or 2 in Radix Ginseng and the Fructus Evodiae.
8, the pharmaceutical composition of claim 6 record, the gastrointestinal drug composition that produces sense of discomfort during wherein above-mentioned taking is drug for peptic ulcer or digestive tract medication.
9, the pharmaceutical composition of claim 6 record, wherein above-mentioned gastrointestinal drug composition is selected from sucralfate, aceglutamide aluminum, gefarnate, sulpiride, glycopyrronium bromide, proglumide, sofalcone, teprenone, Amicos (Banyu), troxipide, plaunotol, ranitidine, cimetidine, famotidine, nizatidine, roxatidine, omeprazole, metoclopramide, aclatonium napadisilate and Trimebutine Maleate.
10, the pharmaceutical composition of claim 1 record, the composition that produces sense of discomfort during wherein above-mentioned taking are the gastrointestinal drug composition medicines in addition that the digestion tract is had side effect.
11, the pharmaceutical composition of claim 10 record, the medicine beyond the wherein above-mentioned gastrointestinal drug composition is a hypnotic and sedative, antipyretic analgesic, the relieving cough and eliminating sputum medicine, antihistaminic, cardiac tonic, the dizzy medicine in town, the diabetes medication, hypotensor, inorganic formulation, hormone drug, antibiotic, anthelmintic and disease-resistant protozoon medicine.
12, the preparation of drug combination method of any record of claim 1～11 is characterized in that using the dry granulation method.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002346393A JP2004175757A (en) | 2002-11-28 | 2002-11-28 | Medicinal composition |
| JP346393/2002 | 2002-11-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1504185A true CN1504185A (en) | 2004-06-16 |
| CN1330378C CN1330378C (en) | 2007-08-08 |
Family
ID=32707312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101186813A Expired - Lifetime CN1330378C (en) | 2002-11-28 | 2003-11-28 | Medicine composition |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2004175757A (en) |
| KR (1) | KR20040047588A (en) |
| CN (1) | CN1330378C (en) |
| HK (1) | HK1065477A1 (en) |
| TW (1) | TW200507876A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507770B (en) * | 2008-07-18 | 2011-01-05 | 天津生机集团股份有限公司 | Traditional Chinese medicine composite for treating horse spasm hernia |
| CN105944104A (en) * | 2016-06-17 | 2016-09-21 | 上海凯宝药业股份有限公司 | Pharmaceutical composition for treating digestive tract ulcer |
| CN117298086A (en) * | 2023-11-29 | 2023-12-29 | 中国中医科学院中药研究所 | Application of sofalcone in preparation of medicines for preventing and/or treating NLRP3 inflammatory corpuscle mediated diseases |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4950551B2 (en) * | 2006-04-25 | 2012-06-13 | 興和株式会社 | Gastrointestinal mucosa protective agent |
| JP6317190B2 (en) * | 2014-06-17 | 2018-04-25 | エスエス製薬株式会社 | Gastrointestinal drug |
| KR102428859B1 (en) * | 2020-05-29 | 2022-08-04 | 동성제약주식회사 | Pharmaceutical composition for oral administration to prevent or treat diseases of the digestive system with safety |
| CN115177593B (en) * | 2022-08-08 | 2023-08-25 | 锦州奥鸿药业有限责任公司 | Glutamine granule and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1114885A (en) * | 1994-05-17 | 1996-01-17 | 内蒙古自治区高等院校科技开发集团赤峰公司 | External-use medicine powder for health care, nourishing kidney and clearing brain |
| JP2000103746A (en) * | 1994-10-27 | 2000-04-11 | Takeda Chem Ind Ltd | Molded product and its production |
| EP1074259A4 (en) * | 1998-04-01 | 2001-06-27 | Chugai Pharmaceutical Co Ltd | Preventives for alcoholic gastritis |
| JP2000191517A (en) * | 1998-12-24 | 2000-07-11 | Lion Corp | Granular composition whose unpalatable taste is masked and its production |
| CN1086928C (en) * | 1999-11-01 | 2002-07-03 | 济南联合大学 | Compound oil-resin flavouring |
-
2002
- 2002-11-28 JP JP2002346393A patent/JP2004175757A/en active Pending
-
2003
- 2003-11-14 TW TW092132009A patent/TW200507876A/en not_active IP Right Cessation
- 2003-11-14 KR KR1020030080560A patent/KR20040047588A/en not_active Application Discontinuation
- 2003-11-28 CN CNB2003101186813A patent/CN1330378C/en not_active Expired - Lifetime
-
2004
- 2004-10-21 HK HK04108298A patent/HK1065477A1/en not_active IP Right Cessation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507770B (en) * | 2008-07-18 | 2011-01-05 | 天津生机集团股份有限公司 | Traditional Chinese medicine composite for treating horse spasm hernia |
| CN105944104A (en) * | 2016-06-17 | 2016-09-21 | 上海凯宝药业股份有限公司 | Pharmaceutical composition for treating digestive tract ulcer |
| CN117298086A (en) * | 2023-11-29 | 2023-12-29 | 中国中医科学院中药研究所 | Application of sofalcone in preparation of medicines for preventing and/or treating NLRP3 inflammatory corpuscle mediated diseases |
| CN117298086B (en) * | 2023-11-29 | 2024-03-08 | 中国中医科学院中药研究所 | Application of sofalcone in preparation of medicines for preventing and/or treating NLRP3 inflammatory corpuscle mediated diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI343818B (en) | 2011-06-21 |
| CN1330378C (en) | 2007-08-08 |
| TW200507876A (en) | 2005-03-01 |
| JP2004175757A (en) | 2004-06-24 |
| KR20040047588A (en) | 2004-06-05 |
| HK1065477A1 (en) | 2005-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1183902C (en) | Process for preparing oral calcium compositions | |
| CN1234230A (en) | Chewing article | |
| US20100010101A1 (en) | Rapid-Melt Compositions and Methods of Making Same | |
| CN1225017A (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
| CN1086708A (en) | Solid drugs and production method thereof with two stage release characteristics | |
| CN1010549B (en) | Conveying system for sweets base substances or active medium | |
| CN1139878A (en) | Intraorally soluble compressed molding and process for producing the same | |
| TW200538162A (en) | Porous cellulose aggregate and molded composition thereof | |
| CN101048155A (en) | Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent for enhanced absorption | |
| CN1736471A (en) | Ginger preparation and preparation process thereof | |
| CN1630523A (en) | Compositions internal or relevant improvement | |
| CN1742957A (en) | Sangju effervescent tablet for treating common cold | |
| CN1762474A (en) | Effervescence tablet for cold | |
| CN1504185A (en) | Medicine composition | |
| CN1965836A (en) | Oral solid formulation and its preparation method | |
| CN1233323C (en) | Orally disintegrating tablet of meloxicam and its preparation | |
| CN1876155A (en) | A medicine for treating gastric disease and preparation method thereof | |
| CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
| CN1302772C (en) | Orally disintegrated sodium ferulate tablet and its prepn process | |
| CN1742956A (en) | Lonicera and Forsythia effervescent tablet for relieving internal heat or fever of humanbody | |
| CN1698663A (en) | Ring form effervescence dosage and preparation method thereof | |
| CN2745572Y (en) | Ring shaped Chinese medicine effervescent form | |
| CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
| CN1245154C (en) | Mouth cavity fast disintegrating tablet of Chinese medicine or natural medical matters and its preparing method | |
| CN1679719A (en) | Compound zedoary oil oral preparation and production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1065477 Country of ref document: HK |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LION CORPORATION Free format text: FORMER OWNER: CHUGAI SEIYAKU KABUSHIKI KAISHA Effective date: 20101026 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20101026 Address after: Tokyo, Japan Patentee after: LION Corp. Address before: Tokyo, Japan Patentee before: Chugai Pharmaceutical Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20070808 |
|
| CX01 | Expiry of patent term |